CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
elotuzumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02843074
NCT02843074Phase 2Completed
CompareCT.gov

Phase 2 Study Assessing Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide and Dexamethasone in Induction, Consolidation and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed With Multiple Myeloma

SCRI Development Innovations, LLC·interventional·Posted Jul 25, 2016·Updated Dec 5, 2023

In Brief

A Phase 2 clinical trial evaluating elotuzumab, Lenalidomide, and 2 other interventions for Multiple Myeloma. Completed, enrolled 53 participants across 6 sites.

Detailed Summary

This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment of transplant eligible, newly diagnosed multiple myeloma patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 25, 2016
Enrollment StartSep 21, 2016
Primary CompletionJul 27, 2021
Study CompletionOct 5, 2021
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 9.9 years ago

Interventions

elotuzumabdrug

Given intravenously (IV)

Lenalidomidedrug

Given by IV

Dexamethasonedrug

Given orally (PO) or by IV

autologous stem cell transplantationprocedure